Live recombined vaccines injected with adjuvant
AssigneeMerial Limited
InventorsJean-Christophe Francis Audonnet, Jules Maarten Minke
Life of this patent
Estimating the term…
Abstract
The recombinant live vaccine comprises a viral vector incorporating and expressing in vivo a heterologous nucleotide sequence, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative. It is in particular a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol (carbomer), in particular cross-linked with an allyl sucrose or with allylpentaerythritol. It may also be a copolymer of maleic anhydride and ethylene cross-linked, for example, with divinyl ether.
Claims49
A vaccine composition against influenza virus in an equine host comprising at least one recombinant virus, selected from the group consisting of canarypox virus, fowlpox virus and pigeonpox virus, containing and expressing in the equine host at least one nucleic acid molecule encoding at least one heterologous influenza protein;
- and, as an adjuvant, a polymer having monomeric units of the formula:
- in which R1 and R2 are identical or different and are H or CH3;
- x is 0 or 1;
- y is 1 or 2;
- and x+y=2.
A vaccine composition against influenza virus in an equine host comprising at least one recombinant virus, selected from the group consisting of canarypox virus, fowlpox virus and pigeonpox virus, containing and expressing at least one nucleic acid molecule encoding at least one heterologous influenza protein;
- and, as an adjuvant, a polymer of acrylic or methacrylic acid.
An immunogenic composition against influenza virus in an equine host comprising at least one recombinant virus, selected from the group consisting of canarypox virus, fowlpox virus and pigeonpox virus, containing and expressing in the equine host at least one nucleic acid molecule encoding at least one heterologous influenza protein;
- and, as an adjuvant, a polymer having monomeric units of the formula:
- in which R1 and R2 are identical or different and are H or CH3;
- x is 0 or 1;
- y is 1 or 2;
- and x+y=2.
An immunogenic composition against influenza virus in an equine host comprising at least one recombinant virus, selected from the group consisting of canarypox virus, fowlpox virus and pigeonpox virus, containing and expressing at least one nucleic acid molecule encoding at least one heterologous influenza protein;
- and, as an adjuvant, a polymer of acrylic or methacrylic acid.
A vaccine composition against influenza virus in an equine host comprising:
- a) at least one recombinant virus, selected from the group consisting of canarypox virus, fowlpox virus and pigeonpox virus, containing and expressing in the equine host, a nucleic acid molecule encoding influenza A2 HA;
- and
- b) a carbomer;
- wherein the vaccine composition, when injected into Welsh Mountain ponies not previously infected by influenza, as a 4 mg/ml carbomer composition containing 107.7TCID50 recombinant virus, achieves at day 14 after injection a mean antibody titre against influenza HA of 155.4±32.9, as measured by single radial hemolysis (SRH).
Dependencies are inferred from the claim text.